Despite success in pre-clinical testing, only two MEK inhibitors, trametinib and cobimetinib, have been approved, both for treatment of BRAF-mutant melanoma.
However, despite promising drug targets and success in pre-clinical testing, only two MEK inhibitors, trametinib (Mekinist) and cobimetinib (Cotellic), have been approved, both for the treatment of BRAF-mutant melanoma [3, 4, 24, 25].
However, whereas in Europe MultiHance is approved both for extrahepatic and hepatic imaging, Primovist is only approved for hepatic imaging.
The HyRAS and HYPITAT studies were approved both primarily for all participating hospitals in the Netherlands by the medical ethics committee of Leiden University Medical Center (HYPITATP04.210) and locally by the hospital board of the participating hospitals.
The Hyras and HYPITAT studies were approved both primarily for all participating hospitals in The Netherlands by the medical ethics committee of Leiden University Medical Centre (HYPITAT: P04·210) and locally by the hospital board of the participating hospitals.
Even if A&A has been approved for both members of a couple, for example, the V.A. cancels the entire pension benefit when the veteran dies.
Two such agents, 5-azacytidine (Vidand) and 5-aza-2′deoxycytidine (decitabine), have been approved for both myelodysplastic syndrome and leukemia [90], [91].
Furthermore, in recent years, monoclonal antibodies to TNF-α (Tumor Necrosis Factor) have been approved for both CD [ 3, 4], including maintenance [ 5], and UC [ 6- 8], in patients who are unresponsive to the aforementioned baseline conventional medications.
Because properties such as replication kinetics, viral RNA synthesis and protein expression appear to be comparable in cell culture- or egg-derived virus strains [ 14], both have been approved for the production of vaccines for human use.
Two vaccines -- Gardasil, made by Merck, and Cervarix, made by GlaxoSmithKline -- have been approved for use in both sexes.
Of the two HPV vaccines on the market — Gardasil, made by Merck, and Cervarix, made by GlaxoSmithKline — only Merck's has been approved for use in both sexes.
